Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-125 with Chemoradiation in Newly Diagnosed MGMT Methylated Glioblastoma
NCT07604285Phase 2Not yet recruiting
- Sponsor
- Myosin Therapeutics
- Start
- Jul 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MT-125 in glioblastoma (GBM), sponsored by Myosin Therapeutics. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
MT-125
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07604285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07604285.